IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) reported that on July 30, 2026, its Board Compensation Committee granted non-qualified stock options to purchase an aggregate of 260,200 shares of common stock to fourteen newly hired employees under the 2023 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a $36.40 exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.

Positive

• Inducement equity grants for 14 new hires totaling 260,200 options
• Exercise price set at market close of $36.40 on grant date
• Four-year vesting structure supports employee retention over time

Negative

• Potential future shareholder dilution from 260,200 additional option shares

News Explained

The grant is an equity award, not a current share issuance: 260,200 options can lead to additional common shares if exercised, creating potential dilution for existing holders; vesting depends on continued service and unfolds over four years.

Market Context

The 1.24% 24-hour reaction for news_id 1075132 is the closest historical comparison for this employe...

Analysis

The 1.24% 24-hour reaction for news_id 1075132 is the closest historical comparison for this employee-equity announcement. The active S-3ASR shelf and recent Net Selling add risk context; future filings provide additional reference points.

Key Figures

Options granted: 260,200 shares Recipients: 14 employees Exercise price: $36.40 per share +4 more

7 metrics

Options granted 260,200 shares Aggregate grant to newly hired employees

Recipients 14 employees Newly hired employees

Exercise price $36.40 per share Equal to the closing price on the grant date

Option term 10 years Term of the stock options

Vesting period 4 years Total vesting period

Initial vesting 25% Vests on the first anniversary of the vesting commencement date

Remaining vesting 75% Vests in equal monthly installments over the following three years

Historical Context

5 past events · Latest: Jul 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 27	Phase 1/2 trial update	Positive	+3.9%	Initiated Part 2 monotherapy expansion in MTAP-deleted pancreatic and lung cancers
Jul 17	Clinical presentation announcement	Neutral	+0.2%	Announced acceptance of four clinical program abstracts for ESMO 2026 presentations
Jun 26	Employee inducement grants	Neutral	+1.2%	Granted options covering 98,000 shares to four newly hired employees
Jun 17	Board leadership change	Neutral	+2.3%	Elected Yujiro S. Hata Chairman and Terry Rosen Lead Independent Director
Jun 15	Phase 1/2 trial update	Positive	+4.3%	Enrolled first patient in IDE892 combination study for MTAP-deleted solid tumors

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All five recent news events produced positive 24-hour price reactions, including neutral announcements such as the prior inducement-grant release.

Key Terms

non-qualified stock options, inducement incentive award plan, nasdaq listing rule 5635(c)(4), exercise price

4 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 260,200 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

inducement incentive award plan financial

"under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan"

An inducement incentive award plan is a package of stock-based pay—like options or restricted shares—given to a newly hired executive or key employee to persuade them to join a company. It matters to investors because such awards can spread ownership thinner and create a cost on the company’s financial statements, while also aligning the new hire’s performance with shareholder value much like a signing bonus that ties future pay to company results.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock options have an exercise price of $36.40 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 30, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 260,200 shares of the Company's common stock to fourteen newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $36.40 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302839570.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What inducement stock options did IDEAYA Biosciences (IDYA) grant on July 30, 2026?

IDEAYA granted non-qualified stock options for 260,200 shares to fourteen new employees. According to IDEAYA, these awards were issued under its 2023 Employment Inducement Incentive Award Plan as hiring inducements consistent with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and term of the new IDEAYA (IDYA) inducement options?

The inducement options have a $36.40 exercise price and a 10-year term. According to IDEAYA, the exercise price equals the July 30, 2026 closing price of its common stock on The Nasdaq Global Select Market.

How do the IDEAYA (IDYA) inducement stock options vest for new employees?

The options vest over four years, with 25% vesting on the first anniversary and 75% vesting monthly over the next three years. According to IDEAYA, vesting requires each employee’s continued service on the applicable vesting dates.

Why did IDEAYA (IDYA) use its 2023 Inducement Plan for these stock option grants?

IDEAYA used its 2023 Inducement Plan to grant equity awards as hiring inducements to individuals not previously employed. According to IDEAYA, the plan is used exclusively for such inducement awards under Nasdaq Listing Rule 5635(c)(4).

How many new employees received IDEAYA (IDYA) inducement stock options in July 2026?

Fourteen newly hired employees received inducement stock options totaling 260,200 shares. According to IDEAYA, these non-qualified options were granted on July 30, 2026 as a material inducement to join the company.

Do the new IDEAYA (IDYA) inducement stock options dilute existing shareholders?

The options may create future dilution because they cover 260,200 shares of common stock. According to IDEAYA, these options are equity awards under its 2023 Inducement Plan and become exercisable as they vest over four years.